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Abstract 
Background: Focal nodular hyperplasia (FNH) are benign lesions in the liver. Although liver resection is generally not 
indicated in these patients, rare indications for surgical approaches indeed exist. We here report on our single‑center 
experience with patients undergoing liver resection for FNH, focussing on preoperative diagnostic algorithms and 
quality of life (QoL) after surgery.
Methods: Medical records of 100 consecutive patients undergoing liver resection for FNH between 1992 and 2012 
were retrospectively analyzed with regard to diagnostic pathways and indications for surgery. Quality of life (QoL) 
before and after surgery was evaluated using validated assessment tools. Student’s t test, one‑way ANOVA, χ2, and 
binary logistic regression analyses such as Wilcoxon–Mann–Whitney test were used, as indicated.
Results: A combination of at least two preoperative diagnostic imaging approaches was applied in 99 cases, of 
which 70 patients were subjected to further imaging or tumor biopsy. In most patients, there was more than one indi‑
cation for liver resection, including tumor‑associated symptoms with abdominal discomfort (n = 46, 40.7 %), balance 
of risk for malignancy/history of cancer (n = 54, 47.8 %/n = 18; 33.3 %), tumor enlargement/jaundice of vascular and 
biliary structures (n = 13, 11.5 %), such as incidental findings during elective operation (n = 1, 0.9 %). Postoperative 
morbidity was 19 %, with serious complications (>grade 2, Clavien–Dindo classification) being evident in 8 %. Perio‑
perative mortality was 0 %. Liver resection was associated with a significant overall improvement in general health 
(very good–excellent: preoperatively 47.4 % vs. postoperatively 68.1 %; p = 0.015).
Conclusions: Liver resection remains a valuable therapeutic option in the treatment of either symptomatic FNH or 
if malignancy cannot finally be ruled out. If clinically indicated, liver resection for FNH represents a safe approach and 
may lead to significant improvements of QoL especially in symptomatic patients.
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Background
Focal nodular hyperplasia (FNH) is the second most 
common benign lesion of the liver most frequently 
occurring in healthy, young and middle-aged women 
[1–3]. As most FNH are asymptomatic and rarely grow, 
these lesions are often discovered incidentally by routine 
abdominal ultrasound [3–5]. Although malignancy can 
safely be ruled out in most cases based on imaging and 
surveillance of these patients, some cases represent diag-
nostic challenge even in these days [3–7]. In this context, 
many different single-center algorithms for the diagnostic 
and therapeutical management of asymptomatic patients 
with incidental benign liver tumors have been initiated 
within the past years, and a consensus paper has recently 
been published to manage these findings on computed 
tomography (CT) in asymptomatic patients [4, 8, 9].
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Diagnostic tools commonly used over the past years 
include ultrasound, nuclear medical procedures (hepato-
biliary scintigraphy with 99Tc) and cross-sectional imag-
ing, e.g. CT. Contrast-enhanced magnetic resonance 
imaging (MRI) scanning has been shown to be the most 
sensitive modality for the characterization of FNH and is 
increasingly applied [10–15]. However, characterization 
might still be challenging, e.g. for single lesions being too 
small to characterize (TSTC lesions) or in patients with a 
history of cancer [13–18].
Furthermore, the differential diagnosis can be difficult 
in cases of atypical appearance (e.g. missing central scar) 
or in elderly patients with underlying chronic liver disease 
at risk for hepatocellular carcinoma (HCC) [16–18]. Inva-
sive diagnostics, e.g. percutaneous biopsy of hypervascu-
lar lesions might be associated with bleeding and tumor 
spread in case of malignancy. Theses techniques may also 
show unclear or misleading results [2–4, 19–21].
The management of benign liver tumors has changed 
over time and is still evolving. Considering the indolent 
natural history of FNH with a low risk for complications 
and no malignant potential, patients with asymptomatic 
FNH should indeed be treated conservatively [1–6, 11, 
12, 19, 20, 22]. A causal relationship between hormo-
nal contraception and growth of FNH has broadly been 
discussed controversially by many authors, whereas a 
minority of physicians might still favor and recommend 
at first to discontinue hormonal contraceptives [22–24].
Surgical approaches should be considered in case of 
tumor enlargement (after discontinued hormonal contra-
ception), as these patients are at increased risk for intra-
hepatic complications, e.g. bile duct compression with 
resulting cholestasis and for rupture or/and acute bleed-
ing [2–6, 10, 20, 22, 25, 26]. Liver resection might also 
be indicated if FNH presents with atypical features and 
malignancy cannot be ruled out [22–26]. Some patients 
indeed report on severe lesion-associated symptoms, e.g. 
abdominal pain or obstruction of large vessels or intrahe-
patic bile ducts and might further benefit from surgical 
approaches. However, many patients suffer from unspe-
cific abdominal discomforts and it remains uncertain 
whether these patients really benefit from liver resections 
[10, 20, 22, 26–29]. Unfortunately, there are only limited 
data evaluating the benefit-risk balance after liver resec-
tions for benign liver lesions [30, 31]. Previous studies 
investigating QoL after liver resection mostly included 
patients with malignant tumors [32, 33]. However, to date 
there are only few studies available investigating QoL 
improvements after liver resection for FNH [22].
We here report on 100 consecutive patients undergo-
ing liver resection for FNH within the past 20  years at 
a single center. The retrospective analysis summarizes 
indications for surgical approaches and the outcome of 
these patients, especially with regard to their QoL after 
liver resection. Liver resection for FNH represents a 
safe approach, being associated with low morbidity and 
no mortality in our series. Especially symptomatic FNH 
patients might benefit from liver resection, as shown by 
significant improvements of their QoL.
Methods
Study population
All records of patients undergoing liver resection for his-
tologically proven FNH at the Department of Surgery, 
University Hospital of Leipzig, between January 1992 and 
October 2012 were analyzed retrospectively. The study 
was approved by the local ethical commission board from 
the University of Leipzig. Patients were subclassified into 
four different time periods (period 1: 1992–1997, period 
2: 1998–2002, period 3: 2003–2007, period 4: 2008–
2012), with regard to improved imaging modalities and 
surgical procedures over the study period.
Before liver resection, patients underwent individual-
ized staging procedures, including abdominal ultrasound, 
CT, MRI, 99Tc hepatibiliary scintigraphy and liver biopsy, 
as indicated (Fig. 1). Symptomatic patients with abdomi-
nal discomfort underwent additional endoscopy of the 
upper and lower GI to exclude extrahepatic disorders. 
Patients with jaundice were all scheduled for endoscopic 
retrograde cholangio-pancreatography (ERCP).
Variables/data collection
Postoperative complications are presented according 
to the Clavien-Dindo-Classification (grades I–V). The 
perioperative mortality was defined as 30-day mortal-
ity. The following variables were assessed: age (years), 
body mass index (kg/m2), sex (male vs. female), hormo-
nal contraception (yes vs. no), hormonal contraception 
(years), history of cancer (yes vs. no), preoperative liver 
blood tests [alanine aminotransferase (ALAT, µmmol/l), 
aspartat aminotransferase (ASAT, µmmol/l), y-glutamyl-
transferase (y-GT, µmmol/l), bilirubin (µmmol/l), alka-
line phopshatase (AP, µmmol/l), prothrombin time (%)], 
duration of the operation (min), extent of resection (≥4 
segments vs. <4 segments; laparoscopic yes vs. no), red 
blood cell concentrate (RBCC) intraoperatively (yes vs. 
no), fresh frozen plasma (FFP) intraoperatively (yes vs. 
no), tumor size (cm),tumor weight (g), number of lesions 
(n), tumor distribution (unilobular vs. multilobular), 
length of intensive care unit (ICU) stay (days), length of 
hospital stay (days) and aminopyrine breath test (ABT).
FNH was verified in all cases after the operation his-
topathologically. Classical FNH were distinguished from 
non-classical FNH, whereas non-classical FNH could be 
divided into three subtypes: teleangiectasic, atypical and 
mixed (hyperplastic or adenomatous) [1, 2, 34].
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Quality of life assessment
All patients were invited to complete a QoL survey ret-
rospectively  (see Additional files 1 and 2). The survey 
was sent by mail to patients’ home addresses in 2013. 
Additionally, patients were interviewed via telephone or 
during clinical visit, as indicated. Patients were asked to 
evaluate their QoL before and after full recovery from 
surgery. As no specific questionnaire exists for patients 
undergoing liver resection for benign liver tumors, a sep-
arate questionnaire was designed using elements from the 
Short-Form 36, McGill Pain Score and European Organi-
zation for Research and Treatment of Cancer Quality of 
Life Questionnaire Core [32, 35, 36]. The survey consists 
of 44 questions, composed of multi-item scales to evalu-
ate physical, emotional, cognitive and social function-
ing. The questionnaire also included 5-symptome-scales 
(bodily pain, nausea/vomiting, abdominal tenderness, 
fatigue and loss of appetite) as well as global scales of 
general health concerns, physical health, social ele-
ments, body image and overall QoL. Likert scale included 
items from 0 (none) to 4 (extreme). The survey included 
questions regarding the pain score before the operation 
as well as 1, 6 and 12  months after surgery. Pain score 
involved 5 items ranging from 0 (none) to 4 (extreme).
Statistical analysis
Statistical data analysis was performed using SPSS soft-
ware (SPSS Inc., Chicago, Illinois, USA, version 18.0). 
Mean and median values were used to describe con-
tinuous data with discrete variables displayed as total, 
frequencies and standard deviations (SD)/range where 
applicable. Student’s t test, one-way ANOVA, χ2 and 
binary logistic regression such as Wilcoxon–Mann–
Whitney test were used where appropriate. Binary 
logistic regression analysis was performed to test the 
association of clinical and operative variables with 
improved QOL, expressed as odds ratios (OR) with a 
95 % confidence interval (CI). Two-tailed p values <0.05 
were considered statistically significant.
Results
Demographic and clinicopathological data
According to our retrospective database, 179 patients 
underwent liver resection for benign lesions between Jan-
uary 1992 and October 2012, of which 100 patients had 
been diagnosed with FNH. During the investigated time 
period 243 patients were diagnosed with FNH at our sur-
gical department, of which 41 % (100) patients received 
an operation. With regard to the different time periods, 
the number of liver resections for FNH decreased in 
recent years from 5.9 per year (range 1–38) between 1992 
and 2007 to 2.75 per year (range 1–11) between 2008 and 
2012 (p = 0.19). Patients’ demographic and clinicopatho-
logical data are summarized in Table 1.
The majority of patients were females (89  %) with 
a median age of 44  years (range 21–71). There were 67 
patients with hormonal contraception with a median 
time of hormone use of 18  years (range 1–35). In 23 
patients hormonal contraceptives were discontinued 
after presumed diagnosis of FNH. Preoperative liver 
blood tests were within the normal ranges; only AP 
and y-GT levels were slightly elevated (AP: 2.5 μkatl/l, 
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Fig. 1 Diagnostic and therapeutical algorithm of our study population
Page 4 of 11Hau et al. Eur J Med Res  (2015) 20:86 
reference range 1.1 and y-GT: 1.4  μmmol/l, reference 
range: 1.2).
The leading indication for liver resection was symptoms 
with abdominal discomfort, in 46 patients (46 %), whereas 
FNH were found as an “incidentaloma” in 54 asympto-
matic patients (54  %). In most patients, there was more 
than one indication for surgery, including abdominal dis-
comfort (n = 46 patients, 40.7 %), uncertainty of diagno-
sis/assumption of malignancy in preoperative imaging 
(n = 54 patients, 47.8 %), including cancer history in 18 of 
the 54 patients (11.5 %) and tumor enlargement/jaundice 
with a rate of growth of >0.5 cm/year or 2–3 cm in com-
parison with initial size in 13 patients (11.5 %) (Fig. 1).
The mean tumor enlargement of the 13 patients was 
2.4  cm (range 0.5–3.0). In 9 patients jaundice with 
compression of vascular and biliary structures were 
observed. Of 18 patients with a history of cancer, patients 
had been diagnosed with colorectal cancer (n  =  2; 
11.11  %), gynecological cancer (breast cancer: n  =  4; 
22.22 %; ovarian or endometrial cancer: n = 5, 27.78 %), 
urogenital cancer (renal cancer n = 2; 11.11 %), pancre-
atic cancer (n = 1; 5.56 %), skin cancer (n = 2; 11.11 %) or 
others (n = 2; 11.11 %).
Regarding the pathological characteristics, median 
tumor diameter was 5.9  cm (range 2–17) with a num-
ber of lesions ranging between 1 and 7. In most patients 
(76 %) tumor distribution was unilobular. Final histology 
revealed classical FNH in 80 % and non-classical FNH in 
20  %. Of these 20 non-classical FNH 11 were classified 
from local pathology as atypical form, 4 as mixed forms 
and 5 as teleangietasic form. Histological examination 
showed a proliferation of the bile duct in 67 specimen 
(67  %), with central scars being observed in 69 (69  %) 
patients.
Diagnostics
Abdominal ultrasound was performed in all patients 
as first approach, with FNH being correctly diagnosed 
in 31  % by this imaging modality. There was no trend 
evident towards a higher sensitivity or specificity of 
abdominal ultrasound for FNH over the investigated 
time periods. 24 Patients were diagnosed incorrectly by 
ultrasound, with a malignant tumor suspected in 10  %, 
hemangioma in 8  % and adenoma in 6  %. Additional 
cross-sectional imaging was performed in 99 of these 
patients, with only one patient being operated following 
ultrasound for acute appendicitis (n = 1) (Table 2).
CT and MRI were performed as first cross-sectional 
imaging approaches in 76 and 23 patients, respectively, 
of which 31 patients (41 %) and 12 patients (52 %) were 
diagnosed correctly with FNH. To increase the degree of 
diagnostic certainty, a second sectional imaging modality 
was chosen in 52 patients.
Of the 45 patients with unclear diagnoses in CT as 
first cross imaging, MRI showed correct diagnoses in 
17 patients. Of the 10 patients with unclear diagnoses 
in MRI as first cross-sectional imaging, none patient 
received a CT (Fig. 1). In totally, FNH was diagnosed cor-
rectly in 17 of 35 (49 %) cases by MRI, in which CT had 
lead to incorrect or uncertain diagnosis. Both modali-
ties results are significantly different from one another 
(p  =  0.006) (Table  3). Interestingly, there was a trend 
towards a higher rate of correct diagnosis for atypical 
FNH, when compared to typical FNH in both CT and 
MRI (Table 4).
Regarding the different time intervals, there were no 
statistical significant differences in sensitivity or specific-
ity of abdominal CT or MRI (Table 2).
Table 1 Demographic and clinicopathological characteris-
tics of our study population (n = 100 patients)
Variables Median (range) or n (%)
Demographics
 Age (years) 44 (21–71)
 Body mass index (kg/m2) 24.9 (17.6–35.3)
Gender
 Female 89 (89 %)
 Male 11 (11 %)
Laboratory values
 ASAT (µmmol/l) 0.39 (0.2–1.15)
 ALAT (µmmol/l) 0.36 (0.15–1.7)
 y‑glutamyltransferase (µmmol/l) 1.4 (0.1–9.6)
 Bilirubin (µmol/l) 8.7 (2–30)
 Alkaline phosphatase (µmol/l) 2.5 (0.7–7.1)
 Prothrombin time (%) 104 (58–134)
Pathology
 Typical FNH 80 (80 %)
 Non‑classical FNH 20 (20 %)
 Tumor size (cm) 5.9 (2–17)
Tumor distribution
 Unilobular 76 (76 %)
 Multilobular 24 (24 %)
 Tumor weight (g) 366.5 (10–1886)
 Number of tumor lesions 1.59 (1–7)
Medical history
 Previous hormone therapy
  Yes 67 (67 %)
  No 33 (33 %)
  Median time of hormone use (years) 18 (1–35)
  Other medicaments (aspirine, steroids, 
antidepressants)
14 (14 %)
 History of cancer
  Yes 18 (18 %)
  No 82 (82 %)
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With regard to the median tumor size of our patients 
(<5.5 vs. >5.5 cm), there were no significant differences 
observed in preoperative accuracy by CT and MRI over 
the observation period (CT, p  =  0.6; MRI, p  =  0.3). 
However, regarding the different time periods, patients 
with FNH >5.5  cm had a trend for a higher preopera-
tive accuracy in the last years (period 1–3 vs. period IV, 
p = 0.07).
99Tc hepatobiliary scintigraphy (until 2005) and per-
cutaneous fine-needle biopsy (FNB) were performed as 
additional diagnostic approaches to cross-sectional imag-
ing in 26 and 21 patients, respectively. Correct diagnosis 
of FNH was achieved by FNB in 10 of 21 cases, whereas 
11 FNB were misdiagnosed as adenoma (n = 5), metas-
tasis and/or assumption of hepatocellular carcinoma 
(n = 3) or inconclusive results (n = 3).
Operative and perioperative outcomes
Median duration of the operation was 163  min (range 
70–445). The majority of patients (68 %) underwent minor 
resections, e.g. atypical resection or (bi)segmentectomy, of 
which 14 patients (22 %) were operated laparoscopically. In 
32 patients (32 %) major liver resections (hemihepatectomy 
or extended hemihepatectomy) were performed. Temporal 
occlusion of the hepatoduodenal ligament (Pringle maneu-
ver) was performed in 60 patients. Transfusion of RBCC 
Table 2 Rate of diagnoses and different imaging modalities of our study population during the different time periods
Modality/diagnosis N Total 1993–1997 (1) 1998–2002 (2) 2003–2007 (3) 2008–2012 (4)
Sonography 100 100 (100 %) 20 (100 %) 31 (100 %) 38 (100 %) 11 (100 %)
 Correct 31 (31 %) 8 (40 %) 6 (19.4 %) 14 (36.8 %) 3 (27.3 %)
 Uncertain 45 (45 %) 8 (40 %) 18 (58.1 %) 17 (44.7 %) 2 (18.2 %)
 Incorrect 24 (24 %) 4 (20 %) 7 (22.6 %) 7 (18.4 %) 6 (54.5 %)
CT 78 78 (100 %) 17 (100 %) 24 (100 %) 31 (100 %) 6 (100 %)
 Correct 33 (42.3 %) 9 (52.9 %) 11 (45.8 %) 11 (35.5 %) 2 (33.3 %)
 Uncertain 28 (35.9 %) 5 (29.4 %) 6 (25 %) 14 (45.2 %) 3 (50 %)
 Incorrect 17 (21.8 %) 3 (17.6 %) 7 (29.2 %) 6 (19.4 %) 1 (16.7 %)
MRI 73 73 (100 %) 12 (100 %) 19 (100 %) 31 (100 %) 11 (100 %)
 Correct 43 (58.9 %) 9 (75 %) 11 (57.9 %) 17 (54.8 %) 6 (54.5 %)
 Uncertain 22 (30.1 %) 2 (16.7 %) 6 (31.6 %) 11 (35.5 %) 3 (27.3 %)
 Incorrect 8 (11 %) 1 (8.3 %) 2 (10.5 %) 3 (9.7 %) 2 (18.2 %)
Table 3 Comparison in  finding preoperative correct vs. 
uncertain/incorrect diagnosis using CT and  MRI. Values 
were illustrated as  frequency (%) from  total examined 
patient collective (n = 52)








































Table 4 Comparison of CT and MRI for finding the distinct 
postoperative histopathological FNH forms
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or FFP was indicated intraoperatively in 9 patients (9  %). 
Median length of stay at ICU was 1.2 days (range 0–6), with 
a median duration of hospital stay of 16 days (range 1–50). 
Perioperative morbidity was observed in 19 patients (19 %), 
perioperative mortality in 0 %. Minor complications (grade 
I, n  =  4; grade II, n  =  7) were observed in 11 patients, 
major complications in 8 patients (grade IIIa, n = 5; grade 
IIIb, n = 2; grade IV, n = 1) (Table 5).
The length of ICU hospital stay (>1 day; p = 0.02), the 
type of surgical procedure (open procedure; p =  0.027, 
major resection; p  =  0.02) and tumor distribution 
(unilobular; p  =  0.04) were associated with statistical 
significant increased rates of complications. Other demo-
graphic, clinicopathological, tumor- and procedure-spe-
cific factors like age (>44 vs. <44 years, p = 0.3), gender 
(male vs. female, p = 0.09), length of intensive care unit 
stay (<14 vs. >14 days, p = 0.07), history of cancer (yes vs. 
no, p = 0.1), transfusion (yes vs. no, p = 0.2) and amino-
pyrine breath test (ABT) (<0.6 vs. >0.6, p = 0.6) showed 
no statistical significance for increased complications.
Quality of life
Questionnaires evaluating QoL were sent to all patients, 
of which 57  % (57 patients) of all patients sent ques-
tionnaires back for further retrospective analysis. They 
were completed at a median of 124  months (range 
6–229 months) postoperatively.
Most patients reported an overall improvement of their 
general health after surgery (“very good–excellent”: pre-
operatively 47.4 % vs. postoperatively 68.1 %; p = 0.015). 
50 patients (88  %) were satisfied with their decision to 
have undergone surgery and would make the same deci-
sion again. Preoperative symptoms included abdomi-
nal pain (n = 36, 63 %), nausea/vomitus (n = 14, 25 %), 
fatigue (n  =  21, 37  %), tenderness (n  =  29, 51  %), loss 
of weight (n =  13, 23 %) and decreased/loss of appetite 
(n = 13, 23 %). The duration of symptoms was reported 
to be up to 6  months, 1 and 3  years preoperatively in 
65, 17.5 and 17.5  %, respectively (Table  6). Reasons for 
Table 5 Operative and  perioperative details of  our study 
population (n = 100 patients)
Variables N (%) or median 
(range)
Extent of resection
 Minor 68 (68 %)
  Laparascopic approach 14 (14 %)
 Major 32 (32 %)
Transfusion intraoperative
 Substitution 9 (9 %)
  Transfusion erythrocyte concentrations 0.23 (0–6)
  Transfusion fresh frozen plasma 0.2 (0–8)
 Operating time (min) 163 (70–445)
 Hospital stay (days) 16 (1–50)
 Intensive care unit (days) 1.2 (0–6)
Complications
 Total complications 19 (19 %)








Table 6 Preoperative symptoms and  duration of  symp-




 None 43 (75.4)
 Mild/moderate 12 (21.1)
 Severe 1 (1.8)
 Extreme 1 (1.8)
Loss of weight
 None 44 (77.2)
 Mild/moderate 7 (12.3)
 Severe 2 (3.5)
 Extreme 4 (7)
Tenderness
 None 28 (49.1)
 Mild/moderate 20 (35.1)
 Severe 5 (8.8)
 Extreme 4 (7)
Fatigue
 None 36 (63.2)
 Mild/moderate 9 (15.8)
 Severe 8 (14)
 Extreme 4 (7)
Decreased appetite
 None 44 (77.2)
 Mild/moderate 7 (12.3)
 Severe 3 (5.3)
 Extreme 3 (5.3)
Duration of symptoms
 <3 months 26 (45.6)
 3–6 months 11 (19.3)
 6–9 months 4 (7)
 9–12 months 6 (10.5)
 1–3 years 3 (5.3)
 >3 years 7 (12.3)
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surgery included impaired lifestyle (n = 7, 12 %), fear of 
complications without therapy (n = 11, 19 %), concerns 
for underlying malignancy (n =  47, 82  %), doctor’s rec-
ommendation (n = 26, 46 %) or general worries (n = 13, 
23 %).
Regarding the general QoL, 49.6 % of patients reported 
a “much better” or “somewhat better” overall QoL after 
surgery, with improvements in both physical and mental 
health. In particular, the proportion of patients reporting 
“a little’’ or ‘‘a lot’’ of limitations with moderate activity 
decreased from 44.1  % preoperatively to 29.4  % post-
operatively (p  <  0.001). Another domain was the men-
tal health status of patients, which also improved after 
surgery. Postoperatively, a larger proportion of patients 
reported to feel calm and peaceful ‘‘at all times’’ or ‘‘most 
times’’ (preoperatively 42.6 % vs. postoperatively 69.1 %; 
p  =  0.005). Patients also reported improvements in 
energy levels, with more patients reporting lots of energy 
‘‘at all times’’ or ‘‘most times’’ (preoperatively 45.6  % vs. 
postoperatively 66.2 %; p < 0.0016). Fewer patients noted 
depressed moods postoperatively (preoperatively 12.7 % 
vs. postoperatively 5.9  %; p  =  0.04). Fewer patients 
reported social impairment postoperatively (physical 
health or emotional problems interfere with social life ‘‘all 
the time’’ or ‘‘often’’: preoperatively 21.9 % vs. postopera-
tively 7.3 %; p < 0.001).
Of 36 patients, whoreported pain preoperatively, 8 
patients (14  %) suffered from mild pain, whereas 28 
patients (49 %) from moderate to extreme pain (Table 7). 
Mean preoperative pain score level did not change 
1  month postoperatively (1.33  ±  0.17, p  =  0.6). Mean 
pain levels decreased significantly over time from 1.49 
(±0.18) preoperatively to 0.82 (±0.17) and 0.35 (±0.09) 
at 6  months and 1  year postoperatively (p =  0.003 and 
p < 0.001). Pain scores decreased over time with no sig-
nificant differences noted between laparascopic and open 
approaches. However, patients undergoing laparoscopic 
liver resection reported 2.3-fold more frequently about 
an improvement of their life quality postoperatively, 
when compared to patients undergoing open operation 
(OR 5.8; 95 % CI 1.1–31.1; p = 0.03).
Analyzing the QoL of all patients undergoing liver 
resection for FNH revealed a benefit especially for 
patients with preoperative symptoms. Patients with 
“moderate-to-extreme” symptoms were more likely to 
report an improvement in general QoL postoperatively, 
when compared to patients with no or only mild symp-
toms preoperatively. In particular, patients who reported 
on ‘‘moderate-to-extreme’’ pain preoperatively were 
more likely to report an improvement in QoL postop-
eratively than patients who initially reported no or mild 
pain (OR, 3.6; 95 % CI 1.1–11.4; p = 0.02). Furthermore, 
the preoperative presence of ‘‘moderate to extreme’’ ten-
derness (OR, 3.5; 95 % CI 1.1–10.5; p = 0.03), ‘‘moder-
ate-to-extreme’’ decreased appetite (OR, 6.3; 95  % CI 
1.2–31.5; p  =  0.02), ‘‘moderate-to-extreme’’ fatigue 
(OR, 3.5; 95 % CI 1.0–11.8; p = 0.04) such as symptoms 
>9  months (OR, 4.7; 95  % 1.3–16.4; p =  0.01) were all 
strongly associated with improved QOL postoperatively 
(Table 8).
Other demographic, clinicopathological, tumor- and 
procedure-specific factors, such as tumor size, extent 
of resection, operative approach, complications in the 
perioperative period, uncertainty of malignancy or fear of 
complications from liver disease had no impact on QOL 
after recovery.
Discussion
This study represents one of the largest retrospective 
analyses, examining patients undergoing liver resec-
tion for FNH to date. Despite remarkable advantages in 
diagnostic modalities within the last years, there remains 
a considerable proportion of misleading preoperative 
diagnosis, especially in patients with atypical forms of 
FNH and history of cancer. Reasons for surgery included 
abdominal discomfort, uncertainty of diagnosis/malig-
nancy and tumor enlargement/jaundice. Our results 
clearly indicate that liver resection can be performed 
safely with major complications evident in only 8 % and 
no mortality. Surgery for FNH is associated with a high 
patient satisfaction and in our study improved QoL, 
especially in symptomatic patients.
Table 7 Comparison of preoperative and postoperative pain level of our study population
Pain level Preoperative First month postoperative 6 months postoperative 1 year postoperative p value
Pain level (%)
 0 (none) 21 (36.8 %) 23 (40.4 %) 25 (43.9 %) 43 (75.4 %)
 1 (mild) 8 (14 %) 9 (15.8 %) 21 (36.8 %) 9 (15.8 %)
 2 (moderate) 12 (21.1 %) 12 (21.1 %) 7 (12.3 %) 4 (7 %)
 3 (severe) 11 (19.3 %) 9 (15.8 %) 4 (7 %) 1 (1.8 %)
 4 (extreme) 5 (8.8 %) 4 (7.0 %) 0 (0 %) 0 (0 %)
Mean ± standard deviation 1.49 ± 0.18 1.33 ± 0.17 0.82 ± 0.12 0.35 ± 0.09 <0.001
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There is an emerging interest in managing incidental 
findings in the liver and pancreas [3–5, 7–9, 37]. Among 
cross-sectional imaging, MRI is considered the most 
reliable imaging method for classifying incidental liver 
lesions, especially after recent improvements, e.g. the 
introduction of the new T1-positive liver specific con-
trast agent, gadoxetic acid (Gd-EOB-DTPA, Primovist or 
Evosit, Bayer Schering Pharma, Germany) [13–18]. How-
ever, even after combining different non-invasive imaging 
modalities, e.g. CT and MRI, and invasive percutaneous 
fine-needle biopsy, diagnostic uncertainty remains in up 
to 40  %. In accordance with the current literature, we 
noted incorrect/uncertain findings on CT and MRI in 58 
and 41  %, respectively, with 40  % remaining incorrect/
uncertain after combined both diagnostic approaches 
[10, 11, 20]. When the CT was incorrect/uncertain, run-
ning an additional MRI did not help establish a more 
correct preoperative diagnosis in our study. There were 
no statistical significant improvements with regard to 
the percentage of correct diagnosis over the investigated 
time periods. Our data show a non significant decrease 
in surgical procedures between 1992 and 2012 in patients 
with histologically proven diagnosis of FNH. The appar-
ent decrease of carried out surgical procedures does not 
necessarily represent a decrease in incidence of FNH, 
but only a decrease of patients who underwent surgical 
procedures for FNH. The reason for the decrease of sur-
gical interventions in FNH patients lies, in our opinion, 
in the more accurate and reliable diagnostic modalities. 
Of note, percentage of incorrect/uncertain diagnosis by 
CT and MRI is likely invalid high, as the patients’ collec-
tive does not represent all patients with FNH, but only 
patients undergoing surgery.
Percutaneous fine-needle biopsy represents another 
diagnostic possibility in the workflow for uncertain liver 
lesions. However, its significance is discussed controver-
sially, as it is associated with an increased bleeding risk in 
hypervascularized lesions and a risk of peritoneal seed-
ing in case of malignancy [2–7, 19–21]. Further, tumor 
biopsy is associated with a low diagnostic sensitivity, with 
only 30–45 % of all biopsy being consistent with the his-
tology of surgical preparations [2, 3, 21]. This could be 
confirmed in our patients’ cohort, where only in 10 of 
21 fine-needle biopsies (47 %) were confirmed by histol-
ogy postoperatively. Apart from operative management 
strategies of symptomatic FNH, percutaneous radiologi-
cal modalities have to be considered and include arterial 
embolization and radiofrequency ablation (RFA), which 
have been published in a few case series [10, 38–40]. 
However, up to date no randomized controlled trials 
exist comparing the outcome of surgical resection with 
percutaneous techniques. Of interest, the major limita-
tion of these interventional techniques is the lack of post-
procedural histology. Therefore, these techniques should 
only be applied if a definitive diagnosis of FNH could 
be secured by preoperative imaging and biopsy-derived 
diagnosis [10].
Most incidentalomas are likely benign without or lit-
tle clinical significance. Committees have recently been 
formed to manage incidental findings on CT and consen-
sus guidelines try to classify patients groups of high risk 
with hepatic and pancreatic lesions [8, 9, 28, 37]. Factors 
like age (>40 years), history of malignancy, hepatic malig-
nant risk factors as well as hepatic dysfunction with or 
without symptoms help to define patients of considerably 
high risk for liver malignancies [8, 9, 37]. In accordance, 
surgery was performed in our cohort because of uncer-
tainty of diagnosis/malignancy in 41 patients, cancer his-
tory in 18 patients and tumor enlargement/jaundice with 
a rate of growth of >0.5 cm/year or 2–3 cm in compari-
son with initial size in 13 patients.
Certainly, special guidelines for benign liver lesions 
are needed to balance cost-intensive long-term follow 
ups by MRI against the risk of unnecessary operations 
Table 8 Analysis of factors associated with improved over-
all quality of life after hepatic surgery of FNH
BMI body mass index, FNH focal nodular hyperplasia
* Statistically significant
Variables Odds ratio (95 % CI) p value
Abdominal pain
 Moderate to extreme 3.6 (1.1–11.4) 0.024*
Tenderness
 Moderate to extreme 3.5 (1.1–10.5) 0.03*
Nausea
 Moderate to extreme 2.5 (0.1–0.7) 0.1
Decreased appetite
 Moderate to extreme 6.3 (1.2–31.5) 0.025*
Fatigue
 Moderate to extreme 3.5 (1.0–11.8) 0.04*
Type of surgery
 Laparascopic approach 5.8 (1.1–31.1) 0.03*
 Minor resection 0.9 (0.2–3.2) 0.9
Complications
 No complications 2.6 (0.5–14.4) 0.2
 Age <40 years 1.4 (0.4–4.4) 0.5
 Female gender 0.5 (0.1–3.1) 0.45
 Tumor size >50 mm 1.8 (0.6–5.3) 0.2
 BMI <25 (kg/m2) 1.7 (0.6–5.1) 0.29
 Hospital stay <16 days 1.1 (0.3–3.2) 0.9
 Unilobular tumor distribution 2.4 (0.5–10.3) 0.2
 Classical FNH 0.4 (0.1–1.4) 0.12
 Symptoms >9 months 4.7 (1.3–16.4) 0.01*
 Uncertainty of malignancy 3.5 (0.6–18.3) 0.1
 Fear of complications from liver disease 1.8 (0.5–7.0) 0.3
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associated with perioperative complications. We need 
to take in account not only improvements in radiologi-
cal findings; due to ongoing improvements in liver sur-
gery with decreased perioperative complications even 
major hepatic resections can be safely performed in 
experienced hepatobiliary centers [19, 22, 29, 30, 41–
43]. Based on our results with low perioperative major 
complications (8  %) and no mortality, this might influ-
ence the process making a decision in these patients. In 
contrast to asymptomatic patients diagnosed with inci-
dentalomas of the liver, 46 patients underwent liver sur-
gery because of abdominal discomfort with nonspecific 
symptoms (nausea, fatigue, decreased appetite, etc.) or 
pain. Although the evaluated symptoms represent typical 
complaints of patients with benign hepatic tumors, they 
are admittedly not specific for FNH. However, the symp-
toms listed in our questionnaire were chosen in support 
of similar studies evaluating QoL in patients with surgery 
for benign hepatic tumors and therefore seem suited to 
evaluate QoL postoperatively [30, 31]. Abdominal pain as 
indication for surgery can be challenging, as it is difficult 
to provide assurances that symptoms will improve after 
surgery [22, 30]. Therefore, liver resection should be con-
sidered only after exclusion of other causes for abdominal 
symptoms and if a relief of symptoms is expected after 
surgery. Only a few reports on QoL improvements after 
liver resection of benign liver tumors exist, with no suf-
ficient data for FNH available [22, 30, 31, 41, 43].
Beside a decreased complication rate after liver surgery, 
long-term outcome represents an important factor for 
evaluating patients for surgery. Our study provides first 
evidence that QoL might improve in patients with symp-
tomatic FNH after liver resection.
The mean patient self-reported pain levels had sig-
nificantly decreased over time. In addition to pain and 
other preoperative symptoms, several further QOL 
domains including physical health, mental/social/emo-
tional health such as general health were evaluated. We 
noted improvements in a wide range of QOL domains 
with 20 % of our patients reporting a significant improve-
ment of general health after liver resection. Further-
more, significant improvements were noted not only in 
physical activities, but also in social and mental health. 
These improvements resulted in greater work productiv-
ity, increased energy level and better social functioning. 
These findings together with the fact that 88 % of patients 
were generally satisfied and would undergo liver surgery 
again seem to prove a positive effect of liver surgery on 
daily life of the patients.
Regarding the different types of surgical approaches, 
e.g. laparascopic vs. open surgery, there were no 
statistically significant differences with regard to 
reported pain levels over time. This is in contrast to 
previous studies by Kneurtz et  al., who noted mark-
edly better pain scores after laparascopic surgery 6 
and 12  months after liver resection [31]. This con-
troversy might be due to the fact that only patients 
scheduled for minor resections were evaluated for 
laparoscopic approaches in our cohort. In accordance 
with similar studies, patients undergoing laparoscopic 
liver resection reported a postoperative improvement 
of QoL of 2.3-fold compared to patients undergoing 
open surgery [31]. Even though an interpretation of 
the QoL data is limited by its retrospective character, 
these results give us a strong impression of patient-
related outcome after resection of benign liver tumors 
and illustrate the benefits of surgery from patient’s 
point of view.
The current study has several limitations that should 
be considered. First, data were collected and analyzed 
retrospectively with a considerable time period between 
surgical procedure and patients’ interview with a 
response rate of approximately 60 %. In this context, the 
collection of data may be influenced by recall bias. For 
example, a possible concern might be that patients with 
better operative outcomes (e.g.: reduction of postopera-
tive pain score, no presence of malignant tumor in final 
postoperative histology, no operative complications) 
answered the QoL survey more often than patients with 
inferior postoperative outcome. This bias could lead to 
an overestimation of the postoperative improvement of 
QoL in our study. In our study, we found an overall com-
plication rate of 19  % concerning all conducted surger-
ies in benign hepatic tumors. The patients who answered 
the QoL questionnaire had an overall complication rate 
of 16  %, comparably to the overall complication rate. 
Therefore, if one may consider the complication rate 
as parameter for negative outcome or negative associa-
tion of the surgical intervention by the patient, a simi-
lar complication rate might contradict the suggested 
recall bias. Another limitation might be that patients 
with the pre-existing diagnosis of a malignant tumor 
might feel more worried by the presence of a malignant 
tumor in the liver and postoperative benign diagnosis 
may have brought these patients more relief compared 
to patients without a cancer history. Patients with a sub-
jective uncertainty of malignancy had a non significant 
increase in QoL after hepatic surgery for FNH. However, 
all other patients with preoperative proven diagnosis 
of a benign tumor nature also showed an insignificant 
increase of QoL. Therefore, we suggest that the histolog-
ically proven certainty of benign tumor nature may play 
an important role in QoL for patients, who are worried 
about the potential malignancy of the tumor; however, 
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patients without worries about tumor malignancy also 
profited from the operation in our study.
Conclusions
This study demonstrates that liver resection for benign liver 
tumors can be performed safely in specialized hepatobiliary 
centers. Despite improvements in diagnostic modalities, 
there remain liver lesions that cannot be specified reliably 
by imaging. In case of uncertain diagnosis, especially in 
patients with a history of malignancy or suspected hepa-
tocellular adenoma, marked tumor enlargement and/or 
jaundice, surgical resection should be considered. In case 
of symptomatic liver lesions, surgical resection should only 
be indicated in patients with tumor-specific symptoms. 
Regarding our results, surgery for FNH is associated with 
marked improvements in patient-reported pain scores as 
well as other QoL domains. Patients with significant pre-
operative symptoms show the most benefit from surgical 
intervention.
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